Breast segment revenue surged over 50% year over year, driving accelerated growth.

In the second quarter of 2026, Axogen reported sales of US$69.73 million, a net loss of US$1.52 million, and lifted its full-year 2026 revenue outlook to at least US$279 million, implying revenue growth of at least 24%. A key highlight was the rapid expansion of Axogen’s breast reconstruction franchise, which drove more than half of quarterly revenue and reshaped the company’s product mix and margin profile. We’ll now explore how Axogen’s upgraded 2026 revenue outlook and breast...

Axogen Inc (AXGN) reports a robust 23% revenue increase, driven by the breast market, while navigating margin pressures and strategic expansion.

AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target markets. The company raised its full-year revenue outlook to at least $279 million, representing gr

AxoGen (AXGN) delivered earnings and revenue surprises of +33.33% and +4.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NZS Capital, LLC, an investment management company, released its “NZS Growth Equity Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Equity markets delivered a strong performance in the second quarter of 2026, driven by demand for AI infrastructure, geopolitical stabilization, and positive earnings reports. The portfolio achieved a gross […]

NZS shifts capital toward AI infrastructure and healthcare leaders